|1.||Kaminski, Mark S: 5 articles (08/2014 - 02/2002)|
|2.||Vose, Julie M: 4 articles (05/2013 - 01/2004)|
|3.||Kroll, Stewart: 4 articles (10/2005 - 02/2002)|
|4.||Kaminski, M S: 4 articles (12/2001 - 03/2000)|
|5.||Fisher, Richard I: 3 articles (08/2014 - 02/2004)|
|6.||Goldsmith, Stanley J: 3 articles (06/2010 - 10/2005)|
|7.||Leonard, John P: 3 articles (06/2010 - 10/2005)|
|8.||Macklis, Roger M: 3 articles (01/2009 - 01/2006)|
|9.||Wahl, Richard L: 3 articles (10/2005 - 02/2002)|
|10.||Wahl, R L: 3 articles (12/2001 - 03/2000)|
|1.||Non-Hodgkin Lymphoma (Lymphosarcoma)
10/20/2005 - "This study is an integrated efficacy analysis of the five clinical trials of tositumomab and iodine-131 tositumomab in patients with relapsed or refractory low-grade, follicular, or transformed low-grade non-Hodgkin's lymphoma (NHL) that resulted in the regulatory approval of the iodine-131 tositumomab by the US Food and Drug Administration. "
02/01/2004 - "Studies are also addressing the role of iodine-131 tositumomab as a component of initial therapy for indolent non-Hodgkin's lymphoma and in additional histologies of non-Hodgkin's lymphoma."
02/01/2004 - "Iodine-131 tositumomab represents one of the most active single agents for the treatment of recurrent indolent and transformed B-cell non-Hodgkin's lymphoma, as demonstrated by several clinical trials summarized in this review. "
01/01/2003 - "Corixa Corporation has announced it expects iodine-131 tositumomab to be approved in the US for non-Hodgkin's lymphoma (NHL). "
09/01/2002 - "Techniques for using Bexxar for the treatment of non-Hodgkin's lymphoma."
10/20/2005 - "Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas."
01/01/2004 - "These data suggest that Bexxar will become an important new option in the treatment of indolent lymphoma."
02/01/2003 - "Lymphoma market turf war imminent, pending Bexxar approval."
03/01/2000 - "Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas."
01/01/2004 - "Targeted radio-immunotherapy with Bexxar produces durable remissions in patients with late stage low grade non-Hodgkin's lymphomas."
|3.||B-Cell Lymphoma (Lymphoma, B Cell)
10/01/1998 - "Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue."
08/01/1998 - "Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience."
02/01/2005 - "To determine overall response (OR) and complete response (CR) rates, response duration, progression-free (PFS) and overall survival and safety with the tositumomab and iodine-131 tositumomab ((131)I tositumomab) therapeutic regimen in patients with indolent, follicular large-cell, or transformed B-cell lymphoma, progressive after rituximab. "
01/01/2003 - "Corixa Corporation has exclusive rights to the patent.A February 2000 media release from GlaxoSmithKline and Corixa Corporation stated that they had been issued a composition patent relating to radiolabelled monoclonal antibodies (including Bexxar) for the treatment of B-cell lymphomas. "
07/01/2001 - "Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens."
03/01/2012 - "Of all patients, 79% had a partial or complete response; 4 of the 8 responders in the EBRT + Bexxar group achieved a durable response of over 2 years, including 3 of the 5 with tumors >5 cm. Three of 9 patients treated with Bexxar alone achieved a durable response over 2 years. "
03/01/2012 - "All 5 patients with a tumor diameter >5 cm were treated with EBRT + Bexxar. "
03/01/2012 - "The median tumor sizes before EBRT + Bexxar and Bexxar alone were 4.8 cm and 3.3 cm, respectively. "
02/15/2002 - "Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. "
07/01/2001 - "It appears that Bexxar and Zevalin will be the first two radiolabeled antibodies that may be available for widespread use in the U.S., and will mark the final introduction of RAIT as an approved cancer treatment modality. "
|5.||Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell)
08/01/2014 - "R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433."
05/01/2013 - "Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial."
|2.||Etoposide (VP 16)
|4.||ibritumomab tiuxetan (Zevalin)
|2.||Drug Therapy (Chemotherapy)
|3.||Stem Cell Transplantation
|5.||Investigational Therapies (Experimental Therapy)